| VEGF | Vascular endothelial growth factor |
| PDGF | Platelet-derived growth factor |
| PDGFR | Platelet-derived growth factor receptor |
| EORTC-STBSG | European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group |
| MAPK | Mitogen-activated protein kinase |
| DFSP | Dermatofibrosarcoma protuberans |
| CR | Complete response |
| PR | Partial response |
| SD | Stable disease |
| PD | Progressive disease |
| DSRCT | Desmoplastic small round cell tumor |
| PD-1 | Programmed cell death 1 |
| PD-L1 | Programmed cell death-ligand 1 |
| SAE | Serious adverse event |
| MHC | Major histocompatibility complex |
| CAR | Chimeric antigen receptor |
| HER2 | Human epidermal growth factor 2 |
| TCR | T-cell receptor |
| CRS | Cytokine release syndrome |